Our Collaborators - Biognosys

Our Collaborators

Our technological innovation and scientific expertise are fueled by an extensive network of over 25 collaborators across the life science industry and academia.

Biognosys has strategic partnerships with all major mass spectrometry instrument vendors and several publicly announced strategic collaborations with industry-leading life science companies to advance drug research and development with next-generation proteomics.


Additionally, Biognosys’ scientific collaborations have resulted in multiple publications in high-ranking journals, numerous posters and presentations at large conferences, and – last but not least – two Grant Programs to support clinical-stage research with large-scale proteomics.

Strategic Investor





In January 2023, Bruker Corporation (Nasdaq: BRKR) made a majority-ownership investment in Biognosys and functions ever since as a strategic investor. The partnership aims at making advanced proteomics research services, software, and kits globally accessible to Biopharma and Biomarker Customers.


“We are delighted to partner with Biognosys to expand our CRO business in the US. We have many common biomarker and biopharma customers, and even more potential customers may prefer a proteomics CRO services expert like Biognosys for rapid, highest quality, and flexible insertion of proteomics into their biomarker or biopharma discovery and development.”

Rohan Thakur, PhD, President of the Bruker Life-Science Mass Spectrometry division



Strategic Collaborators



Featured collaboration: Drug Discovery and Clinical Research.

“Discovery proteomics is increasing its importance to derive functional insights in the early stages of the drug development pipeline. We are thrilled to integrate Biognosys’ proteomics data analysis expertise into Evotec’s pre-clinical and clinical development solutions for the benefit of our biopharma partners.”

Christoph Schaab, PhD, SVP Head of Proteomics & Metabolomics




Featured collaboration: Large-scale Proteomics and Immunopeptidomics

“This extended partnership with Biognosys gives us the ability to validate and expand our findings using state-of-the-art mass-spectrometry technology which will accelerate our path towards bringing discoveries into the practice of personalized oncology.”

Roald Forsberg, PhD, Chief Business Officer

Kymera Therapeutics


Featured collaboration: Precision Proteomics Biomarkers

“Biognosys has been a valued partner as we continue to expand our clinical pipeline across a diverse set of diseases and indications, The company’s high-precision custom proteomics panels enable us to monitor and quantify protein degradation across all aspects of drug development, including preclinical and clinical programs.”

Nello Mainolfi, PhD, Co-Founder, President and CEO




Featured collaboration: Discovery Proteomics Solutions Supporting Biopharma R&D

“The need of our pharma customers to access the next state-of-the-art technology to improve diagnostics and clinical trials is top priority for us. Partnering with Biognosys gives us the added advantage of expanding into proteomics, data analytics and subsequent actionable results, not only in early discovery and translational research but ultimately, in clinical trials impacting patient care.”

Gina Wallar, PhD, President, Pharma Services




Featured collaboration: Spectronaut

“Spectronaut by Biognosys has been an outstanding solution for SCIEX SWATH® acquisition data since the early days of DIA proteomics technology. We are truly excited about what’s coming for SCIEX in this landscape, and we look forward to working with Biognosys to support Spectronaut as a solution for our Proteomics data workflow.”

Jose Castro-Perez, PhD, Senior Director LC/MS Accurate Mass Product Management

Thermo Fisher Scientific



Featured collaboration: Plasma Biomarker Discovery

“Biognosys’ Biomarker Discovery solutions maximize all innovative features of the Thermo Scientific Orbitrap mass spectrometers to analyze the proteome with industry-leading depth. Their unbiased discovery approach, coupled with their state-of-the-art data analysis capabilities, unlocks possibilities for transformative biomarker discovery.”

Andreas Huhmer, PhD, Senior Director Life Sciences Research OMICS Marketing

Scientific Collaborators



Featured collaboration: ACS Chemical Biology Publication

Mechanistic Insights into a CDK9 Inhibitor Via Orthogonal Proteomics Methods



Featured collaboration: Nature Communications Publication

A Machine Learning-based Chemoproteomic Approach to Identify Drug Targets and Binding Sites in Complex Proteomes

Boehringer Ingelheim


Featured collaboration: Drug Discovery

Boehringer Ingelheim and Biognosys Join Forces on Applying Quantitative Proteomics Tools in Drug Discovery

Cancer Research UK (CRUK)


Featured collaboration: AACR 2020 Poster

Quantitative Proteomics Reveals Novel Immunomodulatory Pathways of Resistance to PARP Therapy

Cedilla Therapeutics


Featured collaboration: AACR 2020 Poster

High-Resolution Limited Proteolysis (HR-LiP), a Novel Approach for Target Validation and Lead Compound Optimization

CUIMC Columbia


Featured collaboration: Grant Program

2021 Liver Disease Edition – NAFLD molecular mechanisms

Crown Bioscience


Featured collaboration: Webinar

Biomarker Discovery for Immune Checkpoint Inhibitors



Featured collaboration: Cell PaperPublication

Dynamic 3D Proteomes Reveal Protein Functional Alterations at High Resolution in Situ



Featured collaboration: Webinar

Plasma Proteomics: The Next Frontier Of Biomarker Discovery In The Precision Medicine Era



Featured collaboration: Journal of Proteome Research Publication

Discovery and Qualification of Candidate Urinary Biomarkers of Disease Activity in Lupus Nephritis

Institute Curie


Featured collaboration: AACR 2021 Poster

Immune-related Adverse Effects (irAEs) Associated Proteomic Profile in Late-stage NSCLC Patients after PD-1 Blockade

Institute Gustav Roussy


Featured collaboration: Webinar

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

Ist. Naz. Tumori IRCCS Pascale


Featured collaboration: Webinar

Precision Oncology in Melanoma Patients Treated with Immunotherapy



Featured collaboration: Conference Poster

LC-MRM, a rapid tool for high throughput quantification of protein target expression after mRNA administration

NanoString Technologies


Featured collaboration: AACR 2021 Poster

Response and Skin Toxicity Related Protein Signature in Late-Stage Melanoma Patients after Anti-PD-1 Treatment



Featured collaboration: Diogenes Publication

Analysis of 1508 Plasma Samples by Capillary-Flow Data-Independent Acquisition Profiles Proteomics of Weight Loss and Maintenance



Featured collaboration: ASMS 2020 Poster

Highly Reproducible, Absolute Quantification of >500 Plasma Proteins with PQ500 and SureQuant



Featured collaboration: Grant Program

2020 Immuno-oncology Edition – PRINCE trial proteomics analysis



Featured collaboration: Clinical Proteomics

Roche Presents Data from Biognosys for Use of Discovery Proteomics in Clinical Trials



Featured collaboration: ASCGT 2020 Poster

Validation of CRISPR Gene Knockouts in U2OS Cell Lines with DIA MS-Based Proteomics



Featured collaboration: Nature Communications Publication

SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care


    Close banner

    New: Hyperplex Biomarker Panels

    Custom Panels for Absolute Protein Quantification

    New: Hyperplex Biomarker Panels

    Custom Panels for Absolute Protein Quantification

    Learn More